ARES has delivered its most impressive week in months, jumping nearly 12% after a blowout July 31 earnings print sent the stock to $142.91 — and the question now is whether the analyst upgrades and fading short interest that followed reflect a genuine re-rating or a market that has run ahead of itself.
The July 31 result itself was the catalyst. The stock moved just over 11.6% on the day, validating the cautious-but-constructive setup flagged ahead of the print. Short sellers have continued trimming since: short interest has fallen roughly 2% on the week to 7.6% of the free float, now down nearly 6% from a month ago when it stood closer to 8.7% of float in mid-June. The direction of travel is clear — bears have been reducing steadily since late June, when short shares outstanding were running near 18.4 million. The lending market confirms the lack of pressure: cost to borrow is a negligible 0.71%, down 6% on the week, and availability is a comfortable 273% of short interest — meaning there are nearly three shares available for every one borrowed. That's a loose borrow market with no squeeze mechanics worth watching.
Options positioning has nudged more defensive in the aftermath of the move, though not dramatically so. The put/call ratio is 1.24, running about 1.8 standard deviations above its 20-day mean of 1.16 — the most elevated it has been in several weeks. This is a mild hedging signal, not an alarm: the 52-week PCR high was 3.02, and the current reading looks more like investors locking in some gains than any coordinated bearish repositioning. Taken together with the loose borrow market, positioning looks cautious at the edges but not crowded on the short side.
The Street moved quickly to respond to the earnings beat. JP Morgan's Kenneth Worthington lifted his target from $143 to $153 while holding Overweight — the more notable move given the firm's weight. TD Cowen, RBC Capital, and Oppenheimer all raised targets within 48 hours of results, with RBC pushing to $168 as the most aggressive bull on the desk. BMO's Brennan Hawken raised his target to $134 but stayed at Market Perform, a quiet signal that at least one corner of the Street sees the stock as fairly valued at current levels. The consensus mean target is now $145.83, sitting just above the current price of $142.91 — a narrow implied upside that suggests the Street, in aggregate, is largely caught up with the move. The P/E has re-rated sharply: it's expanded by nearly 3.9 turns over the past month to sit at 21.5x, and EV/EBITDA has widened by 3.2 turns to 19.1x in the same period. The bull case centers on private credit incumbency and strong institutional flows; the bear case flags reliance on illiquid asset classes and the sustainability of recent fundraising growth in a tighter capital environment.
One institutional detail worth noting: Capital Research and Management added nearly 3 million shares in the quarter to June, making it the second-largest institutional holder with 6.6% of shares. Wellington Management also added over 5.3 million shares in the period ending April 30, a meaningful accumulation. Against that, the CEO Michael Arougheti and Executive Director Robert DeVeer each sold just under 83,000 shares at $111.31 on June 30 — well below the current price, so those sales look like pre-earnings housekeeping rather than a directional view on the stock at today's levels.
ARES has broadly outpaced its peer group on the week, though TPG (+11.9%) and OWL (+17.9%) both put in comparable or stronger moves, suggesting this is partly a sector re-rating rather than an ARES-specific story. The next scheduled earnings event is October 30 — which makes the period between now and then a test of whether the 22% one-month re-rating holds, or whether the Street's near-consensus-to-price target signals a stock that has already fully priced the good news.
See the live data behind this article on ORTEX.
Open ARES on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
